GÖRG advises coparion on Series B2 financing round of Tubulis

Frankfurt am Main, 05.04.2024

GÖRG Partnerschaft von Rechtsanwälten mbB, led by Frankfurt partner Dr Markus Söhnchen, provided legal advice to the venture capital fund coparion GmbH & Co. KG on the Series B2 financing round of Tubulis GmbH.

Tubulis GmbH in Planegg received EUR 128 million (USD 138.8 million) through the Series B2 financing round. The financing round was led by EQT Life Sciences and Nextech Invest Ltd. (representing one or more funds managed by them). In addition to coparion, the new US funds Frazier Life Sciences and Deep Track Capital as well as existing investors including Andera Partners, BioMedPartners, Fund+, Bayern Kapital (with ScaleUp-Fonds Bayern), Evotec, Seventure Partners, OCCIDENT and High-Tech Gründerfonds (HTGF) also participated. 

Tubulis is developing a pipeline of uniquely matched antibody drug conjugates (ADCs) with a customised combination of target and drug to develop novel ADCs with superior properties.

The proceeds from the Series B2 will primarily be used to advance the clinical development of Tubulis' pipeline of next-generation ADCs and to provide clinical proof-of-concept for the two lead product candidates TUB-040 and TUB-030.

TUB-040 targets the tumour antigen Napi2b, a well-researched target in ovarian and lung cancer. TUB-030 targets 5T4, an antigen that is frequently overexpressed in solid tumours. Preclinical proof-of-concept data for both candidates will be presented at the annual meeting of the American Association for Cancer Research (AACR) in April. The first Phase 1/2a clinical trial, including dose-escalation and dose-optimisation cohorts, is expected to start in 2024. The funds raised will also be used to expand Tubulis' technology platforms to develop new payloads for the development of versatile and adaptable ADCs. In line with the addition of new US investors, Tubulis plans to expand its footprint by establishing a US facility.

Advisors coparion GmbH & Co. KG

GÖRG Partnerschaft von Rechtsanwälten mbB 
Dr. Markus Söhnchen (Lead Partner, Venture Capital / Corporate Law, Frankfurt)
Dr. Gerhard Gündel (Counsel, Venture Capital / Corporate Law, Frankfurt)
Timo Jans (Associate, Venture Capital / Corporate Law, Frankfurt)

 Newsletter Icon

We inform you about current legal developments in the areas relevant to you.

Subscribe to our Newsletter


Einige der von uns gesetzten Cookies dienen dazu, bestimmte Funktionen unserer Webseiten zu ermöglichen, insbesondere zur Steuerung des Cookie-Banners (damit dieses bei Ihren erneuten Besuchen nicht immer wieder angezeigt wird). Diese Cookies enthalten keine personenbezogenen Daten, insbesondere nicht Ihre IP-Adresse. Andere Cookies, die zu Analysezwecken gesetzt werden (siehe hierzu auch den Abschnitt „Web-Analyse-Tools“), helfen uns zu verstehen, wie Besucher mit unseren Webseiten interagieren. Diese Cookies dienen dazu, die Nutzung unserer Webseiten statistisch zu erfassen und zum Zwecke der Optimierung unseres Angebotes auszuwerten. Die Analyse-Cookies werden bis zu 13 Monate gespeichert.

Save Cancel OK Deny tracking Privacy policy